Study at Anderson Cancer Center

The hospital is a global leader in the treatment of lung cancer, prostate cancer, ovarian cancer, head and neck cancer, colorectal cancer, pancreatic cancer, melanoma and other fields. The 5-year survival rate of most cancers can reach more than 80%. In 2012, the funding and funding from the National Cancer Institute for MD Anderson was also the highest in the United States, with more than $647 million in research funding in 2012
Anderson Cancer Center has more than 20000 employees, including nearly 2000 doctors and more than 500 beds. Every year, it treats more than 19000 inpatients from the United States and other countries, with a daily outpatient volume of 1800. In 2008, a total of 90000 cancer patients were treated, of which 30000 were new patients, distributed in 93 countries and regions, including politicians and business elites. For example, Kun hee Lee, former chairman of SamSung group, South Korea's richest man, went to Anderson Cancer Center in 2000 for surgery and follow-up treatment for lung cancer. The treatment provided by the center for cancer patients includes targeted therapy, surgery, chemotherapy, radiotherapy and proton therapy, immunotherapy and a combination of various therapies. Interdisciplinary team of experts work closely to develop the best treatment for patients. As a Chinese partner of MD Anderson Cancer Center, suno family provides appointment and referral services for Chinese patients
Anderson Cancer Center invests more than 400 million US dollars in basic medical research every year, and has the largest number of research projects funded by the National Cancer Institute (NCI). Currently, the center has 10 NCI research projects, including brain cancer, pancreatic cancer, breast cancer, bladder cancer, prostate cancer, leukemia, ovarian cancer, endometrial cancer, lung cancer and melanoma. Every year, more than 1100 clinical residents come to Anderson Cancer Center for professional training in cancer research and treatment. Anderson Cancer Center has been providing opportunities for Chinese oncologists to learn the most advanced technology in the world for many years. Doctors from almost all famous hospitals in China have studied in Anderson Cancer Center. Many oncologists in major hospitals in China have studied in Anderson Cancer Center. For example, academician Sun Yan, an expert from the Cancer Hospital of the Chinese Academy of Medical Sciences, ranked first in cancer in China

1. the mortality of malignant tumor is the second in the world, second only to cardiovascular and cerebrovascular diseases. The reason why advanced malignant tumors are difficult to treat is that the cancer cells have metastasized at this time

   On the one hand, cancer cells have the ability to proliferate indefinitely. Cancer cells from patients with advanced cancer can proliferate indefinitely in different metastatic foci until they oppress and destroy important organs of human body, such as lung, brain and bone, and then cause organ failure
   On the other hand, in the process of proliferation and growth, cancer cells constantly absorb nutrients, which makes the normal tissues and organs of human body unable to get enough nutrition
   In the long run, there will be emaciation, malnutrition and even cachexia, which will eventually lead to the end of life. No matter which of the above aspects, there is no treatment or drug that can reverse this process, at most, it can only slow down the development of the above process. This is the key to the almost incurable middle and advanced cancer

2. specific to liver cancer. Liver cancer is a serious threat to human health and life in the world. The incidence of liver cancer ranks fifth among all malignant tumors, and the mortality ranks second. The classification of HCC includes hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma and some rare types. Among them, hepatocellular carcinoma (HCC) is the most common pathological type of primary liver cancer [1]. China has always been a "big country of liver cancer". The latest research data show that the mortality rate of liver cancer ranks the third in China, with 460000 new cases and 420000 deaths every year, and the five-year relative survival rate is only 10.1%. According to statistics, the number of new liver cancer cases and deaths in China account for more than half of the number of new cases and deaths in the world [2]

3. the treatment goal of early liver cancer is to strive for cure, and surgery is the most effective treatment. Generally, patients with early liver cancer can get a more optimistic prognosis if they can remove the pathological liver tissue in time, and then give or not give adjuvant treatment after operation

4. the treatment goal of advanced liver cancer is to prolong the progression free survival time and improve the quality of life. Systemic therapy (STT) is a recognized treatment for advanced liver cancer. Systemic therapy for advanced liver cancer includes systemic chemotherapy, local radiotherapy, molecular targeted therapy and immunotherapy

   It is a pity that in the above treatment methods, the traditional treatment methods such as systemic chemotherapy and local radiotherapy have little effect on liver cancer, that is, they can not achieve the established treatment goals, and the survival rate and quality of life can not be significantly improved. At present, only molecular targeted therapy and immunotherapy can bring new breakthrough for the treatment of advanced liver cancer